While it could be a little hard for some to wrap their heads around Tilt Holdings Inc (OTCMKTS: SVVTF), it still could pay off well for marijuana investors.
The pot company completed a four-way reverse merger as well as began trading on the Canadian Securities Exchange last year. Tilt offers distribution of products with the final mile delivery of goods to various dispensaries through its Blackbird subsidiary, and CRM Software to the retailers to help with the purchase.
Tilt Holdings Share Price Analysis
Tilt has shown an archetypal ‘pullback play’ amid a correction that saw a shift from a record high of 3 USD a share this year to a current 1.62 USD per share. Notably, the upward trend has again started to gain some pace so far.
After bottoming, Tilt Holdings is set for a run to get back to over $3 a share which is the immediate resistance. A rally and then a close; that level will undoubtedly affirm a long-term uptrend which will set the pace for stock to edge higher.
TILT Holdings Inc. Overview
Tilt Holdings Inc. is a Canada-based company that delivers products as well as services across the marijuana industry. It provides them through knowledge-based technology systems for both consumers and businesses.
The company went public in early December via a reverse merger in Canada, which allowed it to be listed after making 119 million in the capital at about $4 per share.
The company released its Q4 2018 financial as well as operational highlights whereby it raised $125 million between a strategic private placement offering and a private placement offering with Weston Capital.
During 2018 it was listed on the Canadian Securities Exchange and closed the merger of 4 complementary businesses which evidently provided a foundation for Tilt Holdings.
Also, the pot stock reported revenue of $5.1 million, which was a massive step up compared to the prior year that was nil. Besides, there was a pro forma revenue of $32.8 million. Furthermore, adjusted EBITDA was $3.3 million with that of the prior year being $4.1 million.
Tilt Holdings Acquisition Drive
For any stock to skyrocket, acquisitions have to be behind the wheel, and Tilt Holdings has done its part with a robust of acquisition drive.
Since the year started, the firm has completed a plethora of acquisitions which would prove significant in strengthening its growth. Tilt kick-started the year with the acquisition of Jupiter Research, enabling it to gain access to the leading inhalation as well as vaporization Technology firm.
Having booked over 105 million USD orders in 2018, Jupiter Research also enables Tilt to broaden its product offerings as well as bolster the company.
Furthermore, after Jupiter Research, Tilt acquired Blackbird Holdings which is all set to strengthen its logistics operations as well as software solutions in the marijuana sector. Also, it will support the company’s offering expansion to cannabis business customers and owners.
To ensure that Tilt expands its infrastructure platform and add access to its 13 million customers, it acquired Standard Farms LLC. Standard Farms will also strengthen its product lines since its products circulate in almost 95% of the Pennsylvania dispensaries.
Moreover, the company secured a $20 million credit facility that will strengthen its financial profile – that is undoubtedly a massive step to a larger raise.
What’s Up for the MJ Stock?
One thing that stands out is that Tilt Holdings is among the largest US revenue producing cannabis firms. With the latest change in Tilt’s management, whereby they have named Mark Scatterday as an interim CEO, the company’s sturdy revenue growth is set to continue this year.
Therefore, it looks an ideal play for early movers who eye an opportunity in the marijuana sector given its continuation in expanding its footprint.
For the latest updates on SVVTF and the hottest MJ stocks, sign up below!
Disclosure: We have no position in SVVTF and have not been compensated for this article.
Image courtesy of Pexels
Decision Diagnostics Corp (OTCMKTS:DECN) Explodes On COVID-19 Test Kit Opportunity
Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.
OTCMKTS:DECN Price Analysis
The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.
OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.
Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.
Decision Diagnostics bills itself…
Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?
CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.
The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.
Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.
CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.
Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.
CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment
CytoDyn’s lead drug candidate leronlimab (PRO 140)…
Rainmaker Worldwide Inc (OTCMKTS:RAKR) Looking For Bagholders
On the OTC Markets, there are a lot of pump and dumps. Investors need to protect themselves from these types of scams and one, in particular, is Rainmaker Worldwide Inc (OTCMKTS:RAKR).
OTCMKTS:RAKR Price Action
While the price action recently has been positive, it’s just a matter of time before RAKR is trading in the double zeros again. It’s not a question of if it will happen, but when it will happen.
About Rainmaker Worldwide
According to its profile, Rainmaker Worldwide Inc. is headquartered in Peterborough, Canada, with an innovation and manufacturing center in Rotterdam, Netherlands. Its patented water technology provides economical drinking water wherever it’s needed and at scale. Rainmaker builds two types of energy-efficient, fresh water-producing technologies to participate in this opportunity. 1. Air-to-Water, which harvests fresh water from humidity in the atmosphere. 2. Water-to-Water, which transforms seawater or polluted water into drinking water.
Lack of Fundamentals
The biggest concern facing investors is the lack of fundamentals. OTCMKTS:RAKR has a current market cap of $41 milli0n, but reported just $1000 in sales in the quarter ending September 30, 2019. Making matters worse is that Rainmaker burned through $524,000 in the quarter. Throughout its history, Rainmaker has lost $14.7 million.
EU Horizon 2020 Project and $2.5 million grant
Last September, Rainmaker touted the award of the European Union (EU) Horizon 2020 Project for Rainmaker’s Water to Water Product. According to the press…